Abstract
ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase. After Crizotinib approval by FDA for the management of ALK-rearranged lung cancer, ROS1-positive tumors have been focused. Although significant advancements have been achieved in understanding ROS1 function and its signaling pathways plus recent discovery of small molecules modulating ROS1 protein, a vital need of medicinal chemistry efforts is still required to produce selective and potent ROS1 inhibitors as an important therapeutic strategy for different human malignancies. This review focuses on the current knowledge about different scaffolds targeting ROS1 rearrangements, methods to synthesis, and some biological data about the most potent compounds that have delivered various scaffold structures.
| Original language | English |
|---|---|
| Pages (from-to) | 142-160 |
| Number of pages | 19 |
| Journal | Current Medicinal Chemistry |
| Volume | 23 |
| Issue number | 2 |
| Publication status | Published - 2016 Jan 1 |
Fingerprint
Keywords
- Cancer
- Inhibitor
- Receptor tyrosine kinase
- ROS1 kinase
- Translocation
ASJC Scopus subject areas
- Molecular Medicine
- Pharmacology
Cite this
ROS1 kinase inhibitors for molecular-targeted therapies. / Al-Sanea, M. M.; Abdelazem, A. Z.; Park, B. S.; Yoo, K. H.; Sim, Taebo; Kwon, Y. J.; Lee, S. H.
In: Current Medicinal Chemistry, Vol. 23, No. 2, 01.01.2016, p. 142-160.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - ROS1 kinase inhibitors for molecular-targeted therapies
AU - Al-Sanea, M. M.
AU - Abdelazem, A. Z.
AU - Park, B. S.
AU - Yoo, K. H.
AU - Sim, Taebo
AU - Kwon, Y. J.
AU - Lee, S. H.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase. After Crizotinib approval by FDA for the management of ALK-rearranged lung cancer, ROS1-positive tumors have been focused. Although significant advancements have been achieved in understanding ROS1 function and its signaling pathways plus recent discovery of small molecules modulating ROS1 protein, a vital need of medicinal chemistry efforts is still required to produce selective and potent ROS1 inhibitors as an important therapeutic strategy for different human malignancies. This review focuses on the current knowledge about different scaffolds targeting ROS1 rearrangements, methods to synthesis, and some biological data about the most potent compounds that have delivered various scaffold structures.
AB - ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase. After Crizotinib approval by FDA for the management of ALK-rearranged lung cancer, ROS1-positive tumors have been focused. Although significant advancements have been achieved in understanding ROS1 function and its signaling pathways plus recent discovery of small molecules modulating ROS1 protein, a vital need of medicinal chemistry efforts is still required to produce selective and potent ROS1 inhibitors as an important therapeutic strategy for different human malignancies. This review focuses on the current knowledge about different scaffolds targeting ROS1 rearrangements, methods to synthesis, and some biological data about the most potent compounds that have delivered various scaffold structures.
KW - Cancer
KW - Inhibitor
KW - Receptor tyrosine kinase
KW - ROS1 kinase
KW - Translocation
UR - http://www.scopus.com/inward/record.url?scp=84958238291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958238291&partnerID=8YFLogxK
M3 - Article
C2 - 26438251
AN - SCOPUS:84958238291
VL - 23
SP - 142
EP - 160
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 2
ER -